Postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement in patients with childhood-onset craniopharyngioma.
Humans
Child
Craniopharyngioma
/ complications
Retrospective Studies
Thyroxine
Quality of Life
Deamino Arginine Vasopressin
Neoplasm Recurrence, Local
/ complications
Pituitary Neoplasms
/ epidemiology
Hypothalamic Diseases
/ complications
Pituitary Diseases
/ complications
Hormone Replacement Therapy
Hydrocortisone
craniopharyngioma
hormone replacement therapy
hypothalamic-pituitary axis
long-term follow-up
pediatric patients
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
16
06
2023
accepted:
23
10
2023
medline:
1
12
2023
pubmed:
29
11
2023
entrez:
29
11
2023
Statut:
epublish
Résumé
Hypothalamic-pituitary axis dysfunction is a common complication in post-operative craniopharyngioma(CP) patients, and it greatly impacts the long-term quality of life of such patients. To better understand the effects of postoperative hypothalamic-pituitary dysfunction and long-term hormone replacement therapy in patients with childhood CP, we assessed approximately 200 patients with childhood-onset CP postoperatively. Clinical details of patients with childhood-onset CP who underwent sellar tumor resection in Beijing Children's Hospital and Beijing Tiantan Hospital from 2018 to 2019 were retrieved retrospectively. The participants were followed up to assess the effects of post-operative long-term hormone replacement therapy and assess the tumor recurrence rate. The median age of admission was 8.1 (1.8, 14.3) years. Headache (45.5%), visual impairment (39.5%), and nausea (33.0%) were the most common clinical manifestations. ACP accounted for 95% of all CP cases. The incidence of central adrenal insufficiency and central hypothyroidism within the first week after surgery was 56.2% and 70.3%, respectively. At the same time 85.5% of the patients required at least one dose of desmopressin to control urine output. Total survival and tumor recurrence rates were 98.6% and 26.1%, respectively, with a median follow-up time of 29.7 (19.0, 40.3) months. During the follow-up period, 28.1% patients met the diagnostic criteria for short stature, while 54.4% fit the criteria for obesity. In addition, 94.4% of the patients were taking at least one kind of hormone substitution, and 74.7% were taking three or more. The prevalence of levothyroxine, glucocorticoid, desmopressin, and growth hormone replacement therapy was 87.3%, 77.5%, 78.9% and 31.0%, respectively. The proportion of patients treated with the substitutive combination of levothyroxine, hydrocortisone, and desmopressin was 54.9%. This study is a large-sample systematic postoperative endocrine function evaluation of patients with childhood-onset CP. Due to the high prevalence of post-operative hypothalamic-pituitary dysfunction, patients with CP usually require long-term multiple hormone substitution therapy. Individualized management and accurate hormone replacement dosage for postoperative childhood-onset CP patients are of great importance.
Identifiants
pubmed: 38027203
doi: 10.3389/fendo.2023.1241145
pmc: PMC10657986
doi:
Substances chimiques
Thyroxine
Q51BO43MG4
Deamino Arginine Vasopressin
ENR1LLB0FP
Hydrocortisone
WI4X0X7BPJ
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1241145Informations de copyright
Copyright © 2023 Miao, Fan, Peng, Li, Chen, Bai, Wei, Deng, Zhao, Wu, Ge, Gong and Wu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Neurosurgery. 2018 Oct 1;83(4):631-641
pubmed: 29267973
Chin Med J (Engl). 2004 Mar;117(3):357-60
pubmed: 15043773
Endocr Rev. 2010 Jun;31(3):301-42
pubmed: 20086217
Asian J Neurosurg. 2015 Jan-Mar;10(1):10-6
pubmed: 25767569
Nat Genet. 2014 Feb;46(2):161-5
pubmed: 24413733
J Neurosurg. 2002 Jul;97(1):3-11
pubmed: 12134929
Eur J Endocrinol. 2009 Nov;161(5):671-9
pubmed: 19667040
J Clin Endocrinol Metab. 2015 Feb;100(2):467-74
pubmed: 25375987
Acta Endocrinol (Buchar). 2018 Oct-Dec;14(4):549-555
pubmed: 31149311
Neuro Oncol. 2012 Aug;14(8):1070-8
pubmed: 22735773
J Neurosurg. 1998 Oct;89(4):547-51
pubmed: 9761047
World Neurosurg. 2018 Jan;109:487-496.e1
pubmed: 28987837
J Clin Endocrinol Metab. 2010 Dec;95(12):5395-402
pubmed: 20826582
Clin Endocrinol (Oxf). 2010 Oct;73(4):516-21
pubmed: 20550527
Eur J Endocrinol. 2017 Jun;176(6):755-767
pubmed: 28325825
J Clin Endocrinol Metab. 2018 Aug 1;103(8):2761-2784
pubmed: 29982476
Dtsch Arztebl Int. 2019 May 3;116(18):321-328
pubmed: 31219033
J Clin Endocrinol Metab. 2012 Apr;97(4):1258-67
pubmed: 22319039
Allergy Rhinol (Providence). 2020 Oct 29;11:2152656720964158
pubmed: 33240560
Pituitary. 2021 Aug;24(4):517-522
pubmed: 33506438
Clin Neurol Neurosurg. 2018 Apr;167:162-172
pubmed: 29501046
Nat Rev Dis Primers. 2019 Nov 7;5(1):75
pubmed: 31699993
Childs Nerv Syst. 2021 Mar;37(3):789-797
pubmed: 32617710
Childs Nerv Syst. 2020 Feb;36(2):297-304
pubmed: 31482312
Horm Metab Res. 2018 Sep;50(9):675-682
pubmed: 29959763
Horm Res Paediatr. 2020;93(1):46-57
pubmed: 32460296
Horm Res. 2008;69(4):193-202
pubmed: 18204266
J Neurooncol. 2011 Feb;101(3):463-76
pubmed: 20535527
Clin Endocrinol (Oxf). 2006 May;64(5):556-60
pubmed: 16649976
Eur J Endocrinol. 2012 Jun;166(6):1061-8
pubmed: 22457235
Pituitary. 2013 Mar;16(1):9-17
pubmed: 22886701
J Neurosurg Pediatr. 2021 May 28;:1-8
pubmed: 34049281
Am J Pathol. 2002 Dec;161(6):1997-2001
pubmed: 12466115